{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:49:26Z","timestamp":1780084166119,"version":"3.54.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009145","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000}}],"reference-count":61,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009145.pub2","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T22:34:22Z","timestamp":1326926062000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bezafibrate for primary biliary cirrhosis"],"prefix":"10.1002","volume":"2012","author":[{"given":"Jelena S","family":"Rudic","sequence":"first","affiliation":[{"name":"Clinic of Gastroenterology, Clinical Centre of Serbia; Department of Hepatology; Koste Todorovica 2 Belgrade Serbia 11000"},{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Poropat","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag N","family":"Krstic","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Clinical Centre of Serbia, Medical Faculty, University of Belgrade; Belgrade Serbia 11000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Bjelakovic","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"},{"name":"Medical Faculty, University of Nis; Department of Internal Medicine; Zorana Djindjica 81 Nis Serbia 18000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD009145.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatology Research"},{"issue":"6","key":"10.1002\/14651858.CD009145.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatology Research"},{"issue":"6","key":"10.1002\/14651858.CD009145.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatology Research"},{"issue":"6","key":"10.1002\/14651858.CD009145.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Kurihara T Niimi A Maeda A Shigemoto M Yamashita K Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid American Journal of Gastroenterology 2000 2990 2","DOI":"10.1111\/j.1572-0241.2000.03220.x"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0007|cit7","unstructured":"Nakai S Masaki T Morita T Deguchi A Nishioka M The effect of bezafibrate in patients with primary biliary cirrhosis [abstract] Hepatology 1999 566A"},{"issue":"5","key":"10.1002\/14651858.CD009145.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1272\/jnms1923.63.424","article-title":"A lipid lowering drug (bezafibrate) has a favourable effect on liver enzymes (ALP and gamma-GTP)","volume":"63","author":"Fukuo","year":"1996","journal-title":"Nippon Ika Daigaku Zasshi"},{"issue":"5","key":"10.1002\/14651858.CD009145.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis","volume":"16","author":"Iwasaki","year":"1999","journal-title":"Hepatology Research"},{"issue":"36","key":"10.1002\/14651858.CD009145.pub2-BIB0011|cit11","first-page":"1518","article-title":"A novel treatment for refractory primary biliary cirrhosis?","volume":"47","author":"Miyaguchi","year":"2000","journal-title":"Hepato-Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD009145.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","article-title":"Effect of bezafibrate in primary biliary cirrhosis: a pilot study","volume":"21","author":"Ohmoto","year":"2001","journal-title":"Liver"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0013|cit13","unstructured":"Randomised clinical trial of ursodeoxycholic acid with or without bezafibrate in primary biliary cirrhosis. Ongoing study December 2003."},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.23637","article-title":"American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis","volume":"52","author":"Silveira","year":"2010","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD009145.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"Pt 3","key":"10.1002\/14651858.CD009145.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1042\/bj3140781","article-title":"Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse","volume":"314","author":"Chianale","year":"1996","journal-title":"Biochemical Journal"},{"issue":"3","key":"10.1002\/14651858.CD009145.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.1690453","article-title":"Peroxisome proliferator-activated receptors in inflammation control","volume":"169","author":"Delerive","year":"2001","journal-title":"Journal of Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD009145.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009145.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"6604","key":"10.1002\/14651858.CD009145.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/384039a0","article-title":"The PPARalpha-leukotriene B4 pathway to inflammation control","volume":"384","author":"Devchand","year":"1996","journal-title":"Nature"},{"issue":"2","key":"10.1002\/14651858.CD009145.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the Liver","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","article-title":"How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.","volume":"7","author":"Egger","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD009145.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research","volume":"163","author":"Gluud","year":"2006","journal-title":"American Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD009145.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0026|cit26","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2011, Issue 10. Art. No.: LIVER"},{"issue":"4","key":"10.1002\/14651858.CD009145.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/he.2000.5984","article-title":"Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines","volume":"31","author":"Heathcote","year":"2000","journal-title":"Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD009145.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0030|cit30","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(02)01902-7","article-title":"Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation","volume":"448","author":"Hirano","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0033|cit33","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009145.pub2-BIB0034|cit34","first-page":"A377","article-title":"Japanese abstract","volume":"43","author":"Ishimaru","year":"2002","journal-title":"Acta Hepatologica Japonica (Japanese Society of Hepatology)"},{"issue":"6","key":"10.1002\/14651858.CD009145.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/gast.2001.23984","article-title":"The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood","volume":"120","author":"Jacquemin","year":"2001","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD009145.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009145.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","article-title":"Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy","volume":"97","author":"Kurihara","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD009145.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2005-916323","article-title":"The natural history of PBC: has it changed?","volume":"25","author":"Lee","year":"2005","journal-title":"Seminars in Liver Disease"},{"issue":"4","key":"10.1002\/14651858.CD009145.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD009145.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000063326","article-title":"Lipid-lowering drugs: are adverse effects predictable and reversible?","volume":"97","author":"Muscari","year":"2002","journal-title":"Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD009145.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update","volume":"52","author":"Poupon","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD009145.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1089-3261(03)00102-8","article-title":"The epidemiology of primary biliary cirrhosis","volume":"7","author":"Prince","year":"2003","journal-title":"Clinics in Liver Diseases"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0046|cit46","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"5","key":"10.1002\/14651858.CD009145.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/path.1379","article-title":"High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease","volume":"200","author":"Ros","year":"2003","journal-title":"Journal of Pathology"},{"issue":"4","key":"10.1002\/14651858.CD009145.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"5","key":"10.1002\/14651858.CD009145.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD009145.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","author":"Smit","year":"1993","journal-title":"Cell"},{"issue":"18","key":"10.1002\/14651858.CD009145.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1161\/01.CIR.0000126824.12785.B6","article-title":"Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease","volume":"109","author":"Tenenbaum","year":"2004","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD009145.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archinte.165.10.1154","article-title":"Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome","volume":"165","author":"Tenenbaum","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"The Bezafibrate Infarction Prevention (BIP) Study","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD009145.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0021-9150(80)90011-8","article-title":"Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters","volume":"37","author":"Vessby","year":"1980","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD009145.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD009145.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2125.1984.tb02477.x","article-title":"The short term effect of bezafibrate on hypertriglyceridaemia of moderate to severe uraemia","volume":"18","author":"Williams","year":"1984","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"7644","key":"10.1002\/14651858.CD009145.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD009145.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","author":"Yano","year":"2002","journal-title":"American Journal of Gastroenterology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009145.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T16:58:22Z","timestamp":1725469102000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009145.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009145.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]}}}